Biomarkers in frontotemporal lobar degenerations-Progress and challenges

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 636-648

  Hu, William T ^a   Trojanowski, John Q ^b   Shaw, Leslie M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarker; Diagnosis; Frontotemporal dementia; Tau; Tauopathy; TDP 43

Indexed keywords

BIOLOGICAL MARKER; TAR DNA BINDING PROTEIN; TAU PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; BEHAVIOR CHANGE; EXTRAPYRAMIDAL SYMPTOM; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; LANGUAGE; MOTOR NEURON DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; MUTATION; NEUROIMAGING; RNA-BINDING PROTEIN FUS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 82755161705     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.04.012     Document Type: Review

References (164)

1. Alladi S., Xuereb J., Bak T., Nestor P., Knibb J., Patterson K., Hodges J.R. Focal cortical presentations of Alzheimer's disease. Brain 2007, 130:2636-2645.
2. Alsop D.C., Detre J.A., Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Annals of Neurology 2000, 47:93-100.
3. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Archives of Neurology 1999, 56:673-680.
4. Asmuth J., Zhang H., Grossman M. DTI analysis of white matter deficits in frontotemporal lobar dementia. Neurology 2008, 70:A452.
5. Bak T.H., Crawford L.M., Hearn V.C., Mathuranath P.S., Hodges J.R. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005, 11:268-273.
6. Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J., Adamson J., Sadovnick A.D., Rollinson S., Cannon A., Dwosh E., Neary D., Melquist S., Richardson A., Dickson D., Berger Z., Eriksen J., Robinson T., Zehr C., Dickey C.A., Crook R., McGowan E., Mann D., Boeve B., Feldman H., Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919.
7. Benajiba L., Le Ber I., Camuzat A., Lacoste M., Thomas-Anterion C., Couratier P., Legallic S., Salachas F., Hannequin D., Decousus M., Lacomblez L., Guedj E., Golfier V., Camu W., Dubois B., Campion D., Meininger V., Brice A. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology 2009, 65:470-473.
8. Bian H., Van Swieten J.C., Leight S., Massimo L., Wood E., Forman M., Moore P., de Koning I., Clark C.M., Rosso S., Trojanowski J., Lee V.M., Grossman M. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008, 70:1827-1835.
9. Bilic E., Bilic E., Rudan I., Kusec V., Zurak N., Delimar D., Zagar M. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. European Journal of Neurology 2006, 13:1340-1345.
10. Bjerke M., Portelius E., Minthon L., Wallin A., Anckarsater H., Anckarsater R., Andreasen N., Zetterberg H., Andreasson U., Blennow K. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. International Journal of Alzheimer's Disease 2010, 2010.
11. Boeve B.F., Lang A.E., Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology 2003, 54(Suppl. 5):S15-19.
12. Boeve B.F., Maraganore D.M., Parisi J.E., Ahlskog J.E., Graff-Radford N., Caselli R.J., Dickson D.W., Kokmen E., Petersen R.C. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999, 53:795-800.
13. Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S., Papetti A., Stuani C., Di Luca M., Gennarelli M., Padovani A. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Human Mutation 2009, 30:E974-983.
14. Borroni B., Brambati S.M., Agosti C., Gipponi S., Bellelli G., Gasparotti R., Garibotto V., Di Luca M., Scifo P., Perani D., Padovani A. Evidence of white matter changes on diffusion tensor imaging in frontotemporal dementia. Archives of Neurology 2007, 64:246-251.
15. Borroni B., Malinverno M., Gardoni F., Alberici A., Parnetti L., Premi E., Bonuccelli U., Grassi M., Perani D., Calabresi P., Di Luca M., Padovani A. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008, 71:1796-1803.
16. Brettschneider J., Widl K., Ehrenreich H., Riepe M., Tumani H. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neuroscience Letters 2006, 404:347-351.
17. Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000, 1:293-299.
18. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., Benedum T.E., Kilbourn M.R., Skovronsky D., Kung H.F. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. Journal of Nuclear Medicine 2009, 50:1887-1894.
19. Chow T.W., Binns M.A., Freedman M., Stuss D.T., Ramirez J., Scott C.J., Black S. Overlap in frontotemporal atrophy between normal aging and patients with frontotemporal dementias. Alzheimer Disease and Associated Disorders 2008, 22:327-335.
20. Collette F., Amieva H., Adam S., Hogge M., Van der Linden M., Fabrigoule C., Salmon E. Comparison of inhibitory functioning in mild Alzheimer's disease and frontotemporal dementia. Cortex: A Journal Devoted to The Study of the Nervous System and Behavior 2007, 43:866-874.
21. Corrado L., Ratti A., Gellera C., Buratti E., Castellotti B., Carlomagno Y., Ticozzi N., Mazzini L., Testa L., Taroni F., Baralle F.E., Silani V., D'Alfonso S. High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Human Mutation 2009, 30:688-694.
22. Davidsson P., Sjogren M., Andreasen N., Lindbjer M., Nilsson C.L., Westman-Brinkmalm A., Blennow K. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Research 2002, 109:128-133.
23. Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., Sjogren M., Blennow K. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002, 13:611-615.
24. Davies R.R., Kipps C.M., Mitchell J., Kril J.J., Halliday G.M., Hodges J.R. Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Archives of Neurology 2006, 63:1627-1631.
25. Dickson D.W., Bergeron C., Chin S.S., Duyckaerts C., Horoupian D., Ikeda K., Jellinger K., Lantos P.L., Lippa C.F., Mirra S.S., Tabaton M., Vonsattel J.P., Wakabayashi K., Litvan I. Office of rare diseases neuropathologic criteria for corticobasal degeneration. Journal of Neuropathology and Experimental Neurology 2002, 61:935-946.
26. Esmonde T., Giles E., Gibson M., Hodges J.R. Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy. Journal of Neurology 1996, 243:638-643.
27. Finch N, Baker M., Crook R., Swanson K., Kuntz K., Surtees R., Bisceglio G., Rovelet-Lecrux A., Boeve B., Petersen R.C., Dickson D.W., Younkin S.G., Deramecourt V., Crook J., Graff-Radford N.R., Rademakers R. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009, 132:583-591.
28. Forman M.S., Farmer J., Johnson J.K., Clark C.M., Arnold S.E., Coslett H.B., Chatterjee A., Hurtig H.I., Karlawish J.H., Rosen H.J., Van Deerlin V., Lee V.M., Miller B.L., Trojanowski J.Q., Grossman M. Frontotemporal dementia: clinicopathological correlations. Annals of Neurology 2006, 59:952-962.
29. Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., DeCarli C.S., Turner R.S., Koeppe R.A., Higdon R., Minoshima S. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130:2616-2635.
30. Foulds P., McAuley E., Gibbons L., Davidson Y., Pickering-Brown S.M., Neary D., Snowden J.S., Allsop D., Mann D.M. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathologica 2008, 116:141-146.
31. Freibaum B.D., Chitta R.K., High A.A., Taylor J.P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. Journal of Proteome Research 2010, 9:1104-1120.
32. Gass J., Cannon A., Mackenzie I.R., Boeve B., Baker M., Adamson J., Crook R., Melquist S., Kuntz K., Petersen R., Josephs K., Pickering-Brown S.M., Graff-Radford N., Uitti R., Dickson D., Wszolek Z., Gonzalez J., Beach T.G., Bigio E., Johnson N., Weintraub S., Mesulam M., White C.L., Woodruff B., Caselli R., Hsiung G.Y., Feldman H., Knopman D., Hutton M., Rademakers R. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics 2006, 15:2988-3001.
33. Geser F., Brandmeir N.J., Kwong L.K., Martinez-Lage M., Elman L., McCluskey L., Xie S.X., Lee V.M., Trojanowski J.Q. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Archives of Neurology 2008, 65:636-641.
34. Gordon E., Rohrer J.D., Kim L.G., Omar R., Rossor M.N., Fox N.C., Warren J.D. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010, 74:666-673.
35. Gorno-Tempini M.L., Brambati S.M., Ginex V., Ogar J., Dronkers N.F., Marcone A., Perani D., Garibotto V., Cappa S.F., Miller B.L. The logopenic/phonological variant of primary progressive aphasia. Neurology 2008, 71:1227-1234.
36. Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M., Phengrasamy L., Rosen H.J., Johnson J.K., Weiner M.W., Miller B.L. Cognition and anatomy in three variants of primary progressive aphasia. Annals of Neurology 2004, 55:335-346.
37. Gros-Louis F., Andersen P.M., Dupre N., Urushitani M., Dion P., Souchon F., D'Amour M., Camu W., Meininger V., Bouchard J.P., Rouleau G.A., Julien J.P. Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21777-21782.
38. Gross R.G., Hu W.T., McMillan C.T., Gunawardena D., Lee V.M., Trojanowski J.Q., Grossman M. Prediction of underlying Alzheimer's disease in corticobasal syndrome. American Academy of Neurology Annual Meeting 2010.
39. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nature Reviews Neurology 2010, 6:88-97.
40. Grossman M., Libon D.J., Forman M.S., Massimo L., Wood E., Moore P., Anderson C., Farmer J., Chatterjee A., Clark C.M., Coslett H.B., Hurtig H.I., Lee V.M., Trojanowski J.Q. Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Archives of Neurology 2007, 64:1601-1609.
41. Grossman M., McMillan C., Moore P., Ding L., Glosser G., Work M., Gee J. What's in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer's disease, frontotemporal dementia and corticobasal degeneration. Brain 2004, 127:628-649.
42. Grossman M., Xie S.X., Libon D.J., Wang X., Massimo L., Moore P., Vesely L., Berkowitz R., Chatterjee A., Coslett H.B., Hurtig H.I., Forman M.S., Lee V.M., Trojanowski J.Q. Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology 2008, 70:2036-2045.
43. Gunawardena D., Ash S., McMillan C., Avants B., Gee J., Grossman M. Why are patients with progressive nonfluent aphasia nonfluent?. Neurology 2010, 75:588-594.
44. Hodges J.R., Davies R.R., Xuereb J.H., Casey B., Broe M., Bak T.H., Kril J.J., Halliday G.M. Clinicopathological correlates in frontotemporal dementia. Annals of Neurology 2004, 56:399-406.
45. Hodges J.R., Mitchell J., Dawson K., Spillantini M.G., Xuereb J.H., McMonagle P., Nestor P.J., Patterson K. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010, 133:300-306.
46. Hsiung G.Y., Fok A., Feldman H.H., Rademakers R., Mackenzie I.R. rs5848 polymorphism and serum progranulin level. Journal of the Neurological Sciences 2010.
47. Hu F., Padukkavidana T., Vaegter C.B., Brady O.A., Zheng Y., Mackenzie I.R., Feldman H.H., Nykjaer A., Strittmatter S.M. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010, 68:654-667.
48. Hu W.T., Chen-Plotkin A., Arnold S.E., Grossman M., Clark C.M., Shaw L.M., McCluskey L., Elman L., Karlawish J., Hurtig H.I., Siderowf A., Lee V.M., Soares H., Trojanowski J.Q. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathologica 2010, 120:385-399.
49. Hu W.T., Chen-Plotkin A., Arnold S.E., Grossman M., Clark C.M., Shaw L.M., Pickering E., Kuhn M., Chen Y., McCluskey L., Elman L., Karlawish J., Hurtig H.I., Siderowf A., Lee V.M., Soares H., Trojanowski J.Q. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathologica 2010, 119:669-678.
50. Hu W.T., Chen-Plotkin A., Grossman M., Arnold S.E., Clark C.M., Shaw L.M., McCluskey L., Elman L., Hurtig H.I., Siderowf A., Lee V.M., Soares H., Trojanowski J.Q. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 2010.
51. Hu W.T., McMillan C., Libon D.J., Leight S., Forman M.S., Lee V.M., Trojanowski J.Q., Grossman M. Multi-modal predictors for Alzheimer's disease in non-fluent primary progressive aphasia. Neurology 2010, 75:595-602.
52. Hu W.T., Rippon G.W., Boeve B.F., Knopman D.S., Petersen R.C., Parisi J.E., Josephs K.A. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders 2009, 24:1375-1379.
53. Hu W.T., Seelaar H., Josephs K.A., Knopman D.S., Boeve B.F., Sorenson E.J., McCluskey L., Elman L., Schelhaas H.J., Parisi J.E., Kuesters B., Lee V.M., Trojanowski J.Q., Petersen R.C., van Swieten J.C., Grossman M. Survival profiles of patients with frontotemporal dementia and motor neuron disease. Archives of Neurology 2009, 66:1359-1364.
54. Hu W.T., Wang Z., Lee V.M., Trojanowski J.Q., Detre J.A., Grossman M. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010, 75:881-888.
55. Hu W.T., Zhang H., McMillan C., Lee V.M., Trojanowski J.Q., Grossman M. Distinct white matter tract changes in frontotemporal dementia associated with FTLD and Alzheimer's disease pathology or CSF biomarkers. American Academy of Neurology Annual Meeting 2010.
56. Hutchinson A.D., Mathias J.L. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. Journal of Neurology, Neurosurgery, and Psychiatry 2007, 78:917-928.
57. Hutton M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001, 56:S21-25.
58. Ishii K., Sakamoto S., Sasaki M., Kitagaki H., Yamaji S., Hashimoto M., Imamura T., Shimomura T., Hirono N., Mori E. Cerebral glucose metabolism in patients with frontotemporal dementia. Journal of Nuclear Medicine 1998, 39:1875-1878.
59. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology 2010, 9:119-128.
60. Josephs K.A. Frontotemporal dementia and related disorders: deciphering the enigma. Annals of Neurology 2008, 64:4-14.
61. Josephs K.A., Dickson D.W. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Movement Disorders 2003, 18:1018-1026.
62. Josephs K.A., Parisi J.E., Knopman D.S., Boeve B.F., Petersen R.C., Dickson D.W. Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Archives of Neurology 2006, 63:506-512.
63. Josephs K.A., Petersen R.C., Knopman D.S., Boeve B.F., Whitwell J.L., Duffy J.R., Parisi J.E., Dickson D.W. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006, 66:41-48.
64. Josephs K.A., Tang-Wai D.F., Edland S.D., Knopman D.S., Dickson D.W., Parisi J.E., Petersen R.C., Jack C.R., Boeve B.F. Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Archives of Neurology 2004, 61:1881-1884.
65. Josephs K.A., Whitwell J.L., Boeve B.F., Knopman D.S., Petersen R.C., Hu W.T., Parisi J.E., Dickson D.W., Jack C.R. Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease. Movement Disorders 2010, 25:1246-1252.
66. Josephs K.A., Whitwell J.L., Dickson D.W., Boeve B.F., Knopman D.S., Petersen R.C., Parisi J.E., Jack C.R. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging 2008, 29:280-289.
67. Josephs K.A., Whitwell J.L., Knopman D.S., Boeve B.F., Vemuri P., Senjem M.L., Parisi J.E., Ivnik R.J., Dickson D.W., Petersen R.C., Jack C.R. Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology 2009, 73:1443-1450.
68. Josephs K.A., Whitwell J.L., Parisi J.E., Petersen R.C., Boeve B.F., Jack C.R., Dickson D.W. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. European Journal of Neurology 2010, 17:969-975.
69. Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., Pradat P.F., Camu W., Meininger V., Dupre N., Rouleau G.A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics 2008, 40:572-574.
70. Kasai T., Tokuda T., Ishigami N., Sasayama H., Foulds P., Mitchell D.J., Mann D.M., Allsop D., Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathologica 2009, 117:55-62.
71. Kawajiri M., Mogi M., Higaki N., Tateishi T., Ohyagi Y., Horiuchi M., Miki T., Kira J.I. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 2009, 119:341-344.
72. Kertesz A., Martinez-Lage P., Davidson W., Munoz D.G. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000, 55:1368-1375.
73. Kertesz A., McMonagle P. Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. Journal of the Neurological Sciences 2010, 289:138-143.
74. Kertesz A., McMonagle P., Blair M., Davidson W., Munoz D.G. The evolution and pathology of frontotemporal dementia. Brain 2005, 128:1996-2005.
75. Kim E.J., Rabinovici G.D., Seeley W.W., Halabi C., Shu H., Weiner M.W., DeArmond S.J., Trojanowski J.Q., Gorno-Tempini M.L., Miller B.L., Rosen H.J. Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery, and Psychiatry 2007, 78:1375-1378.
76. Kipps C.M., Davies R.R., Mitchell J., Kril J.J., Halliday G.M., Hodges J.R. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dementia and Geriatric Cognitive Disorders 2007, 23:334-342.
77. Knopman D.S., Jack C.R., Kramer J.H., Boeve B.F., Caselli R.J., Graff-Radford N.R., Mendez M.F., Miller B.L., Mercaldo N.D. Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year. Neurology 2009, 72:1843-1849.
78. Knopman D.S., Kramer J.H., Boeve B.F., Caselli R.J., Graff-Radford N.R., Mendez M.F., Miller B.L., Mercaldo N. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008.
79. Koedam E.L., Van der Flier W.M., Barkhof F., Koene T., Scheltens P., Pijnenburg Y.A. Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. Alzheimer Disease and Associated Disorders 2010, 24:242-247.
80. Kuhle J., Lindberg R.L., Regeniter A., Mehling M., Steck A.J., Kappos L., Czaplinski A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. European Journal of Neurology 2009, 16:771-774.
81. Kuhnlein P., Sperfeld A.D., Vanmassenhove B., Van Deerlin V., Lee V.M., Trojanowski J.Q., Kretzschmar H.A., Ludolph A.C., Neumann M. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Archives of Neurology 2008, 65:1185-1189.
82. Kuiperij H.B., Verbeek M.M. Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?. Neurobiology of Aging 2010, 10.1016/j.neurobiolaging.2010.08.011.
83. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (New York, NY) 2009, 323:1205-1208.
84. Lee S.E., Seeley W.W., Wilson S., Growdon M., Jang J., Rankin K.P., Jagust W.J., Weiner M.W., Gorno-Tempini M.L., Miller B.L., Rabinovici G.D. Correlates of Alzheimer's pathology in corticobasal syndrome. American Academy of Neurology Annual Meeting 2010.
85. Libon D.J., Massimo L., Moore P., Coslett H.B., Chatterjee A., Aguirre G.K., Rice A., Vesely L., Grossman M. Screening for frontotemporal dementias and Alzheimer's disease with the Philadelphia Brief Assessment of Cognition: a preliminary analysis. Dementia and Geriatric Cognitive Disorders 2007, 24:441-447.
86. Libon D.J., Xie S.X., Moore P., Farmer J., Antani S., McCawley G., Cross K., Grossman M. Patterns of neuropsychological impairment in frontotemporal dementia. Neurology 2007, 68:369-375.
87. Ling H., O'Sullivan S.S., Holton J.L., Revesz T., Massey L.A., Williams D.R., Paviour D.C., Lees A.J. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010, 133:2045-2057.
88. Listerud J., Powers C., Moore P., Libon D.J., Grossman M. Neuropsychological patterns in magnetic resonance imaging-defined subgroups of patients with degenerative dementia. Journal of International Neuropsychological Society 2009, 15:459-470.
89. Litvan I., Agid Y., Jankovic J., Goetz C., Brandel J.P., Lai E.C., Wenning G., D'Olhaberriague L., Verny M., Chaudhuri K.R., McKee A., Jellinger K., Bartko J.J., Mangone C.A., Pearce R.K. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996, 46:922-930.
90. Loewenstein D.A., Acevedo A., Ownby R., Agron J., Barker W.W., Isaacson R., Strauman S., Duara R. Using different memory cutoffs to assess mild cognitive impairment. American Journal Geriatric Psychiatry 2006, 14:911-919.
91. Lomen-Hoerth C., Anderson T., Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
92. Mackenzie I.R. The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathologica 2007, 114:49-54.
93. Mackenzie I.R., Baker M., Pickering-Brown S., Hsiung G.Y., Lindholm C., Dwosh E., Gass J., Cannon A., Rademakers R., Hutton M., Feldman H.H. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006, 129:3081-3090.
94. Mackenzie I.R., Neumann M., Bigio E.H., Cairns N.J., Alafuzoff I., Kril J., Kovacs G.G., Ghetti B., Halliday G., Holm I.E., Ince P.G., Kamphorst W., Revesz T., Rozemuller A.J., Kumar-Singh S., Akiyama H., Baborie A., Spina S., Dickson D.W., Trojanowski J.Q., Mann D.M. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica 2009, 117:15-18.
95. Mattsson N., Blennow K., Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clinical Chemistry and Laboratry Medicine 2010, 48:603-607.
96. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosen E., Aarsland D., Visser P.J., Schroder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttila T., Wallin A., Jonhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
97. McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Archives of Neurology 2001, 58:1803-1809.
98. McMurtray A.M., Chen A.K., Shapira J.S., Chow T.W., Mishkin F., Miller B.L., Mendez M.F. Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia. Neurology 2006, 66:517-522.
99. McNeill R., Sare G.M., Manoharan M., Testa H.J., Mann D.M., Neary D., Snowden J.S., Varma A.R. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2007, 78:350-355.
100. Mendez M.F., Shapira J.S., McMurtray A., Licht E., Miller B.L. Accuracy of the clinical evaluation for frontotemporal dementia. Archives of Neurology 2007, 64:830-835.
101. Mesulam M., Wicklund A., Johnson N., Rogalski E., Leger G.C., Rademaker A., Weintraub S., Bigio E.H. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Annals of Neurology 2008, 63:709-719.
102. Mesulam M.M. Slowly progressive aphasia without generalized dementia. Annals of Neurology 1982, 11:592-598.
103. Mesulam M.M. Primary progressive aphasia. Annals of Neurology 2001, 49:425-432.
104. Mitchell R.M., Freeman W.M., Randazzo W.T., Stephens H.E., Beard J.L., Simmons Z., Connor J.R. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72:14-19.
105. MJFF (2010). The Michael J. Fox Foundation for Parkinson's Research. Parkinson's Progression Markers Initiative.
106. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
107. Mukherjee O., Pastor P., Cairns N.J., Chakraverty S., Kauwe J.S., Shears S., Behrens M.I., Budde J., Hinrichs A.L., Norton J., Levitch D., Taylor-Reinwald L., Gitcho M., Tu P.H., Tenenholz Grinberg L., Liscic R.M., Armendariz J., Morris J.C., Goate A.M. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Annals of Neurology 2006, 60:314-322.
108. Murray R., Neumann M., Forman M.S., Farmer J., Massimo L., Rice A., Miller B.L., Johnson J.K., Clark C.M., Hurtig H.I., Gorno-Tempini M.L., Lee V.M., Trojanowski J.Q., Grossman M. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007, 68:1274-1283.
109. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
110. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, NY) 2006, 314:130-133.
111. Pasinetti G.M., Ungar L.H., Lange D.J., Yemul S., Deng H., Yuan X., Brown R.H., Cudkowicz M.E., Newhall K., Peskind E., Marcus S., Ho L. Identification of potential CSF biomarkers in ALS. Neurology 2006, 66:1218-1222.
112. Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., Jack C.R., Jagust W.J., Shaw L.M., Toga A.W., Trojanowski J.Q., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010, 74:201-209.
113. Petzold A., Keir G., Warren J., Fox N., Rossor M.N. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neuro-degenerative Diseases 2007, 4:185-194.
114. Pick A. Uber die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Medicinische Wochenschrift 1892, 165-167.
115. Poste G. Bring on the biomarkers. Nature 2011, 469:156-157.
116. Rabinovici G.D., Furst A.J., O'Neil J.P., Racine C.A., Mormino E.C., Baker S.L., Chetty S., Patel P., Pagliaro T.A., Klunk W.E., Mathis C.A., Rosen H.J., Miller B.L., Jagust W.J. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
117. Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., O'Neil J.P., Lal R.A., Dronkers N.F., Miller B.L., Gorno-Tempini M.L. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Annals of Neurology 2008, 64:388-401.
118. Rademakers R., Eriksen J.L., Baker M., Robinson T., Ahmed Z., Lincoln S.J., Finch N., Rutherford N.J., Crook R.J., Josephs K.A., Boeve B.F., Knopman D.S., Petersen R.C., Parisi J.E., Caselli R.J., Wszolek Z.K., Uitti R.J., Feldman H., Hutton M.L., Mackenzie I.R., Graff-Radford N.R., Dickson D.W. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics 2008, 17:3631-3642.
119. Rascovsky K., Hodges J.R., Kipps C.M., Johnson J.K., Seeley W.W., Mendez M.F., Knopman D., Kertesz A., Mesulam M., Salmon D.P., Galasko D., Chow T.W., Decarli C., Hillis A., Josephs K., Kramer J.H., Weintraub S., Grossman M., Gorno-Tempini M.L., Miller B.M. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Disease and Associated Disorders 2007, 21:S14-18.
120. Rascovsky K., Salmon D.P., Hansen L.A., Thal L.J., Galasko D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Neuropsychology 2007, 21:20-30.
121. Ratnavalli E., Brayne C., Dawson K., Hodges J.R. The prevalence of frontotemporal dementia. Neurology 2002, 58:1615-1621.
122. Rogers T.T., Ivanoiu A., Patterson K., Hodges J.R. Semantic memory in Alzheimer's disease and the frontotemporal dementias: a longitudinal study of 236 patients. Neuropsychology 2006, 20:319-335.
123. Rosen H.J., Gorno-Tempini M.L., Goldman W.P., Perry R.J., Schuff N., Weiner M., Feiwell R., Kramer J.H., Miller B.L. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002, 58:198-208.
124. Rosen H.J., Narvaez J.M., Hallam B., Kramer J.H., Wyss-Coray C., Gearhart R., Johnson J.K., Miller B.L. Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia. Alzheimer Disease and Associated Disorders 2004, 18:202-207.
125. Rosen H.J., Perry R.J., Murphy J., Kramer J.H., Mychack P., Schuff N., Weiner M., Levenson R.W., Miller B.L. Emotion comprehension in the temporal variant of frontotemporal dementia. Brain 2002, 125:2286-2295.
126. Rosso S.M., Donker Kaat L., Baks T., Joosse M., de Koning I., Pijnenburg Y., de Jong D., Dooijes D., Kamphorst W., Ravid R., Niermeijer M.F., Verheij F., Kremer H.P., Scheltens P., van Duijn C.M., Heutink P., van Swieten J.C. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003, 126:2016-2022.
127. Ruetschi U., Zetterberg H., Podust V.N., Gottfries J., Li S., Hviid Simonsen A., McGuire J., Karlsson M., Rymo L., Davies H., Minthon L., Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Experimental Neurology 2005, 196:273-281.
128. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
129. Seeley W.W., Bauer A.M., Miller B.L., Gorno-Tempini M.L., Kramer J.H., Weiner M., Rosen H.J. The natural history of temporal variant frontotemporal dementia. Neurology 2005, 64:1384-1390.
130. Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Gorno-Tempini M.L. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Archives of Neurology 2008, 65:249-255.
131. Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52.
132. Shaw L.M., Korecka M., Clark C.M., Lee V.M., Trojanowski J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews 2007, 6:295-303.
133. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology 2009, 65:403-413.
134. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Figurski M., Coart E., Blennow K., Soares H., Simon A.J., Lewczuk P., Dean R.A., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica 2011.
135. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., Shaw C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (New York, NY) 2008, 319:1668-1672.
136. Steinacker P., Hendrich C., Sperfeld A.D., Jesse S., von Arnim C.A., Lehnert S., Pabst A., Uttner I., Tumani H., Lee V.M., Trojanowski J.Q., Kretzschmar H.A., Ludolph A., Neumann M., Otto M. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Archives of Neurology 2008, 65:1481-1487.
137. Strong M.J., Lomen-Hoerth C., Caselli R.J., Bigio E.H., Yang W. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Annals of Neurology 2003, 54(Suppl. 5):S20-23.
138. Suarez J., Tartaglia M.C., Vitali P., Erbetta A., Neuhaus J., Laluz V., Miller B.L. Characterizing radiology reports in patients with frontotemporal dementia. Neurology 2009, 73:1073-1074.
139. Trojanowski J.Q., Arnold S.E., Karlawish J.H., Brunden K., Cary M., Davatzikos C., Detre J., Gaulton G., Grossman M., Hurtig H., Jedrziewski K., McCluskey L., Naylor M., Polsky D., Schellenberg G.D., Siderowf A., Shaw L.M., Van Deerlin V., Wang L.S., Werner R., Xie S.X., Lee V.M. Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimer's Dementia 2010, 6:150-155.
140. Trojanowski J.Q., Vandeerstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W.Z., Weiner M.W., Jack C.R., Jagust W., Toga A.W., Lee V.M., Shaw L.M. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Dementia 2010, 6:230-238.
141. Tsuboi Y., Yamada T. Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 1994, 57:859-861.
142. Urwin H., Josephs K.A., Rohrer J.D., Mackenzie I.R., Neumann M., Authier A., Seelaar H., Van Swieten J.C., Brown J.M., Johannsen P., Nielsen J.E., Holm I.E., Dickson D.W., Rademakers R., Graff-Radford N.R., Parisi J.E., Petersen R.C., Hatanpaa K.J., White C.L., Weiner M.F., Geser F., Van Deerlin V.M., Trojanowski J.Q., Miller B.L., Seeley W.W., van der Zee J., Kumar-Singh S., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Bigio E.H., Deng H.X., Halliday G.M., Kril J.J., Munoz D.G., Mann D.M., Pickering-Brown S.M., Doodeman V., Adamson G., Ghazi-Noori S., Fisher E.M., Holton J.L., Revesz T., Rossor M.N., Collinge J., Mead S., Isaacs A.M. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica 2010, 120:33-41.
143. Van Deerlin V.M., Sleiman P.M., Martinez-Lage M., Chen-Plotkin A., Wang L.S., Graff-Radford N.R., Dickson D.W., Rademakers R., Boeve B.F., Grossman M., Arnold S.E., Mann D.M., Pickering-Brown S.M., Seelaar H., Heutink P., van Swieten J.C., Murrell J.R., Ghetti B., Spina S., Grafman J., Hodges J., Spillantini M.G., Gilman S., Lieberman A.P., Kaye J.A., Woltjer R.L., Bigio E.H., Mesulam M., Al-Sarraj S., Troakes C., Rosenberg R.N., White C.L., Ferrer I., Llado A., Neumann M., Kretzschmar H.A., Hulette C.M., Welsh-Bohmer K.A., Miller B.L., Alzualde A., de Munain A.L., McKee A.C., Gearing M., Levey A.I., Lah J.J., Hardy J., Rohrer J.D., Lashley T., Mackenzie I.R., Feldman H.H., Hamilton R.L., Dekosky S.T., van der Zee J., Kumar-Singh S., Van Broeckhoven C., Mayeux R., Vonsattel J.P., Troncoso J.C., Kril J.J., Kwok J.B., Halliday G.M., Bird T.D., Ince P.G., Shaw P.J., Cairns N.J., Morris J.C., McLean C.A., DeCarli C., Ellis W.G., Freeman S.H., Frosch M.P., Growdon J.H., Perl D.P., Sano M., Bennett D.A., Schneider J.A., Beach T.G., Reiman E.M., Woodruff B.K., Cummings J., Vinters H.V., Miller C.A., Chui H.C., Alafuzoff I., Hartikainen P., Seilhean D., Galasko D., Masliah E., Cotman C.W., Tunon M.T., Martinez M.C., Munoz D.G., Carroll S.L., Marson D., Riederer P.F., Bogdanovic N., Schellenberg G.D., Hakonarson H., Trojanowski J.Q., Lee V.M. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics 2010, 42:234-239.
144. Van Rooij F.G., Schelhaas H.J., Lammers G.J., Verbeek M.M., Overeem S. CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2009, 10:487-489.
145. Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., Shaw C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (New York, NY) 2009, 323:1208-1211.
146. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters 2000, 285:49-52.
147. Vanvoorst W.A., Greenaway M.C., Boeve B.F., Ivnik R.J., Parisi J.E., Eric Ahlskog J., Knopman D.S., Dickson D.W., Petersen R.C., Smith G.E., Josephs K.A. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism & Related Disorders 2008, 14:376-378.
148. Vass R., Ashbridge E., Geser F., Hu W.T., Grossman M., Clay-Falcone D., Elman L., McCluskey L., Lee V.M., Van Deerlin V.M., Trojanowski J.Q., Chen-Plotkin A.S. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica 2010, 121:373-380.
149. Verwey N.A., van der Flier W.M., Blennow K., Clark C., Sokolow S., De Deyn P.P., Galasko D., Hampel H., Hartmann T., Kapaki E., Lannfelt L., Mehta P.D., Parnetti L., Petzold A., Pirttila T., Saleh L., Skinningsrud A., Swieten J.C., Verbeek M.M., Wiltfang J., Younkin S., Scheltens P., Blankenstein M.A. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Annals of Clinical Biochemistry 2009, 46:235-240.
150. Wang Y., Klunk W.E., Huang G.F., Debnath M.L., Holt D.P., Mathis C.A. Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. Journal of Molecular Neuroscience 2002, 19:11-16.
151. Whitwell J.L., Avula R., Senjem M.L., Kantarci K., Weigand S.D., Samikoglu A., Edmonson H.A., Vemuri P., Knopman D.S., Boeve B.F., Petersen R.C., Josephs K.A., Jack C.R. Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. Neurology 2010, 74:1279-1287.
152. Whitwell J.L., Jack C.R., Parisi J.E., Knopman D.S., Boeve B.F., Petersen R.C., Ferman T.J., Dickson D.W., Josephs K.A. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007, 130:1148-1158.
153. Whitwell J.L., Josephs K.A., Rossor M.N., Stevens J.M., Revesz T., Holton J.L., Al-Sarraj S., Godbolt A.K., Fox N.C., Warren J.D. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Archives of Neurology 2005, 62:1402-1408.
154. Whitwell J.L., Warren J.D., Josephs K.A., Godbolt A.K., Revesz T., Fox N.C., Rossor M.N. Voxel-based morphometry in tau-positive and tau-negative frontotemporal lobar degenerations. Neuro-degenerative Diseases 2004, 1:225-230.
155. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brasic J.R., Ye W., Hilton J., Lyketsos C., Kung H.F., Joshi A.D., Skovronsky D.M., Pontecorvo M.J. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). Journal of Nuclear Medicine 2010, 51:913-920.
156. Wuolikainen A., Hedenstrom M., Moritz T., Marklund S.L., Antti H., Andersen P.M. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotrophic Lateral Sclerosis 2009, 10:229-236.
157. Xiong L., Xuereb J.H., Spillantini M.G., Patterson K., Hodges J.R., Nestor P.J. Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology. Journal of Neurology, Neurosurgery, and Psychiatry 2011, 82:254-260.
158. Yamada T., Moroo I., Koguchi Y., Asahina M., Hirayama K. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy. Acta Neurologica Scandinavica 1994, 89:42-46.
159. Yasui K., Inoue Y., Kanbayashi T., Nomura T., Kusumi M., Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Journal of the Neurological Sciences 2006, 250:120-123.
160. Zamboni G, Huey E.D., Krueger F., Nichelli P.F., Grafman J. Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates. Neurology 2008, 71:736-742.
161. Zetterberg H., Jacobsson J., Rosengren L., Blennow K., Andersen P.M. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. European Journal of Neurology 2007, 14:1329-1333.
162. Zhang Y., Schuff N., Du A.T., Rosen H.J., Kramer J.H., Gorno-Tempini M.L., Miller B.L., Weiner M.W. White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain 2009, 132:2579-2592.
163. Zhou J., Greicius M.D., Gennatas E.D., Growdon M.E., Jang J.Y., Rabinovici G.D., Kramer J.H., Weiner M., Miller B.L., Seeley W.W. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 2010, 133:1352-1367.
164. Zhou J.Y., Afjehi-Sadat L., Asress S., Duong D.M., Cudkowicz M., Glass J.D., Peng J. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. Journal of Proteome Research 2010, 9:5133-5141.